<DOC>
	<DOCNO>NCT02224313</DOCNO>
	<brief_summary>The purpose study compare vaginal health premenopausal postmenopausal woman use oral `` estradiol '' 14 day `` estradiol '' `` progesterone '' 14 day .</brief_summary>
	<brief_title>Effect Oral Estradiol Progesterone Therapy Vaginal Cytokines Postmenopausal Women</brief_title>
	<detailed_description>This research project recruit 10 healthy , premenopausal woman ( age 20-40 years-old ) regular menstrual cycle interval 24-35 day duration 2-7 day 20 healthy postmenopausal woman ( age 45-60 years-old ) intact uterus least 12 month 36 month spontaneous amenorrhea . Premenopausal woman receive study medication ( ) . Postmenopausal woman `` randomize '' one study group describe . - Oral `` estradiol '' 0.5 mg tablet 14 day , oral `` estradiol '' 0.5 mg tablet `` progesterone '' 100 mg capsule 14 day - Oral `` estradiol '' 1.0 mg tablet 14 day , oral `` estradiol '' 1.0 mg tablet `` progesterone '' 100 mg capsule 14 day</detailed_description>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Premenopausal Postmenopausal woman : 1 . Female age 20 40 year ( premenopausal arm ) , OR female age 45 65 year ( postmenopausal arm ) willing participate study , document signing informed consent form . 2 . Postmenopausal woman intact uterus least 12 month spontaneous amenorrhea ( postmenopausal arm ) , OR premenopausal woman regular menstrual cycle interval 2435 day duration 27 day ( premenopausal arm ) . 3 . No oral hormone therapy 8 week transdermal vaginal hormone therapy 4 week prior study . 4 . Willing use oral hormone therapy study period ( postmenopausal woman ) . 5 . Willing abstain use product ( study medication ) contain estrogen , progestin , progesterone throughout study participation . 6 . Have general good health . 7 . Willing refrain sexual intercourse 48 hour vaginal sample collection . 8 . Willing abstain use vaginal product 7 day vaginal sample collection . To participate study , subject must NOT 1 . Be allergic estrogen progesterone product 2 . Have active genital infection inflammation base vaginal wet preparation , pH , whiff test KOH , preparation 2.1 Vulvovaginal candidiasis , trichomonas vaginitis bacterial vaginitis 2.2 Sexually transmitted disease include herpes simplex viral infection , gonorrhea Chlamydia 3 . Have know contraindication oral hormone therapy allergy use estradiol and/or progesterone 4 . Have use estrogen alone estrogen/progestin following time period : 4.1 Vaginal hormone product ( ring , cream , gel ) within 30 day prior screen 4.2 Transdermal estrogen alone estrogen/progestin product within 4 week prior screen 4.3 Oral estrogen and/or progestin therapy within 8 week prior screen 4.4 Progestational implant , estrogen estrogen/progestational injectable drug therapy within 3 month prior screen 4.5 Estrogen pellet therapy progestational injectable drug therapy within 6 month prior screen 4.6 Percutaneous estrogen lotions/gels within 4 week prior screen 5 . Have use tamoxifen , raloxifene selective estrogen receptor modulators ( SERMs ) therapy within 8 week prior screen 6 . Have use intrauterine device ( IUD ) within 8 week prior screen 7 . Have use vaginal product ( pessary , tampon , tablet , douche ) within 7 day prior screen 8 . Have evidence cervical , vaginal , vulvar intraepithelial neoplasia cancer 9 . Have past current history breast cancer , endometrial cancer endometrial hyperplasia , hypertriglyceridemia venous thromboembolism 10 . Be immunocompromised patient include human immunodeficiency viral infection , chronic glucocorticoid use active treatment immunosuppressive agent 11 . Have history current evidence thromboembolism 12 . Have evidence uncontrolled Hypertension Blood pressure &gt; 140/100 mmHg 13 . Have confirm Diabetes Mellitus 14 . Currently smoke 15 . For sexually active premenopausal woman , protected pregnancy sterilization , condom use , abstinence , sex relationship</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>vaginal cytokine</keyword>
</DOC>